Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants
Objective To evaluate the impact of gentamicin exposure on sensorineural hearing loss (SNHL) in very low birth weight (VLBW) infants. Methods Exposure to gentamicin was determined in infants born between 1993 and 2010 at a gestational age 32 weeks and/or with a birthweight 1500 g, who presented with SNHL during the first 5 years of life. For each case, we selected two controls matched for gender, gestational age, birthweight, and year of birth. Results We identified 25 infants affected by SNHL, leading to an incidence of SNHL of 1.58% in our population of VLBW infants. The proportion of infants treated with gentamicin was 76% in the study group and 70% in controls (p 0.78) The total cumulated dose of gentamicin administered did not differ between the study group (median 10.2 mg/kg, Q1 Q3 1.6 13.2) and the control group (median 7.9 mg/kg, Q1 Q3 0 12.8, p 0.47) The median duration of gentamicin treatment was 3 days both in the study group and the control group (p 0.58) Maximum predicted trough serum levels of gentamicin, cumulative area under the curve and gentamicin clearance were not different between cases and controls. Conclusion The impact of gentamicin on SNHL can be minimized with treatments of short duration, monitoring of blood levels and dose adjustment.
PloS one